A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol

Amir Anushiravani 1, Homayoon Vahedi 1, Hafez Fakheri 2, Fariborz Mansour-ghanaei 3, Iraj Maleki 2, Siavosh Nasser-Moghaddam 1, Hasan Vosoughinia 4, Mohammad Reza Ghadir 5, Ahmad Hormati 5.9, Nayyereh Aminisani 6, Amir Reza Radmard 7, Bardia Khosravi 1, Bahar Saberzadeh-Ardestani 1, Masoud Malekzadeh 1, Sudabeh Alatab 1, Anahita Sadeghi 1, Sarvenaz Salahi 8, Reza Malekzadeh 1, Ali Reza Sima 1,*

ABSTRACT

BACKGROUND

The COVID-19 pandemic has affected the health care infrastructure dramatically, with abundant resources necessarily being redirected to COVID-19 patients and their care. Also, patients with chronic diseases like inflammatory bowel disease (IBD) may be affected in several ways during this pandemic.

METHODS

We used the Iranian registry of Crohn’s and colitis (IRCC) infrastructure. We called and sent messages to follow-up and support the care of all registered patients. Besides, we prepared and distributed educational materials for these patients and physicians to reduce the risk of COVID-19 infection. We risk-stratified them and prepared outpatient clinics and hospitalization guidance for IBD patients.

RESULTS

Of 13165 Iranian patients with IBD, 51 have been diagnosed as having COVID-19. IBD patients made 1920 hotline calls. Among the patients with suspicious presentations, 14 COVID-19 infections were diagnosed. Additionally, 1782 patients with IBD from five provinces actively phone-called among whom 28 definite cases were diagnosed.

CONCLUSION

IBD patients’ follow-up could help in diagnosing the affected IBD patients with COVID-19. Additionally, the performance of protective actions and preparing the patients and physicians for decisive proceedings are the principles of protection of IBD patients.

KEYWORDS:
Protocols, Care, Inflammatory bowel disease, COVID-19

© 2020 The Author(s). This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
INTRODUCTION

Concerns about the prevention of the novel coronavirus-2019 infection are increasing as the whole population is susceptible to the disease caused by this virus. Individuals with elder age and underlying comorbidities, especially any type of cardiovascular dysfunctions, diabetes, and immunodeficiency, are at higher risk of COVID-19 related complications, including acute respiratory distress syndrome (ARDS), septic shock, sepsis, and multi-organ failure. Therefore, healthcare systems should aim to design principles for patients with comorbidities to reduce the risk of COVID-19 infection for this population.

On the other hand, COVID-19 has led the healthcare systems to use all the capacity of health centers to diagnose, treat, and care for the affected patients. As a result, patients with chronic comorbidities such an inflammatory bowel disease (IBD), who have been under health centers’ observation through the scheduled regular visits, can be exposed to the infection. Decreasing the risk of infection by limiting these follow-up visits can also lead to lower disease flare-up and complications, especially for patients with IBD. Therefore, programming for adjustment of routine cares, encouragement of health care providers to enter this modified program, the proper and timely reaction of the healthcare team to inform the patients and their families about the modality of performance of the program, as well as providing appropriate care at this time, are essentials to be considered for patients with chronic underlying comorbidities. These changes seem to be pivotal in maintaining the appropriate care of these patients and decreasing the chance of complications.

Although conceptually, patients with IBD seem to be at higher risk of developing COVID-19 and affected by its complications, a report by the IBD Elite Union of China, which follow up patients with IBD at this time, stated that there were no proven COVID-19 cases among IBD patients as of March 17, 2020.

In this report, we describe our experience and approach to patients with IBD during the SARS-COVID-19 pandemic in Iran to reduce the risk of COVID-19 infection, adjusting the routine care of these patients, detecting the IBD patients with COVID-19 infection, and planning for the possible complications during COVID-19 pandemic.

MATERIALS AND METHODS

We designed a protocol for supporting patients with IBD during COVID-19 outbreak with three aspects, including reducing the risk of COVID-19 for such patients, adjustment of routine care to support the patients, as well as screening the patients for COVID-19 infection and management of COVID-19 for the infected patients with IBD, simultaneously (figure 1 and table 1).

We used the Iranian registry of Crohn’s and colitis (IRCC) infrastructure. IRCC is a prospective multi-center registry with the cooperation of 449 gastroenterologists from all provinces of Iran, which has gathered the information of patients with IBD in 31 provinces since 2017.

After the announcement of the first case of COVID-19 in Iran, the preparations of educational materials for patients with IBD and updated recommendation for physicians have been started through the literature review. The purpose of providing the educational materials and recommendations was to inform physicians and patients with IBD about the modalities, which can reduce the risk of COVID-19 infection both for patients and healthcare providers.

The educational package was sent weekly through text messages and “WhatsApp” for all 13512 patients with IBD who have been registered in IRCC, since 2007. On the other hand, daily messages about the lack of higher risk of COVID for patients with IBD, the importance of continuing to take all medications, and the need to be in contact with the IBD team in case of the presence of COVID-19 manifestations, were sent through Instagram (Table 2).

Due to the need for easy access of patients to IBD team specialists, a hotline was designed for patients. It was advised for immediate hotline call in case of fever, cough, dyspnea, myalgia, sore throat, diarrhea, nausea, vomiting, or abdominal pain. This possibility was notified via text message to all registered patients with IBD. Additionally, active follow-up was performed through phone-call for assessing COVID-19 manifestation among patients with IBD in provinces with a higher frequency of IBD. During the calls with symptomatic patients, all known presentations of COVID-19 were checked, and the duration of symptoms was asked for each symptom.

Based on the risk factors, the British Society of Gastroenterology (BSG) designed a risk stratification system for patients with IBD, shown in Table 3.
All patients with IBD have been categorized based on the BSG risk stratification system as high, moderate, and low risk. All high-risk patients were recommended to be monitored closely by telephone. The other two groups should be educated and followed up based on the presence of the clinical characteristics of COVID-19.

Suspected patients were referred for clinical assessment with a chest computed tomography (CT). The outcomes of CT scans were evaluated by two expert radiologists who were determined in each province. After the diagnosis of COVID-19, the affected patients were eventually treated according to national protocols. According to the national protocol, PCR testing was performed only for patients who needed hospital admission, and for others, decisions were made based on clinical assessment and symptoms.

Fig.1: The flowchart of the Iranian registry of Crohn’s and colitis for screening the patients with IBD for COVID-19.
were made solely based on CT scans. We followed up the patients with IBD with confirmed COVID-19 infection at least up two weeks after the diagnosis.

On the other hand, the physicians who visited and followed-up the IBD patients had access to a web-based platform to report the cases of IBD with COVID-19 infection. The report form contained the following items: age, sex, weight, height, province, the activity of IBD, the therapeutic medications, year and month of COVID-19 diagnosis, name of the center/physician, risk factors of COVID-19, the outcome of COVID-19 (alive, death), the treatment considered for COVID-19, hospital admission (name of the hospital, length of stay, need for ventilation, and intensive care unit [ICU] admission).

All elective screening procedures, which have been appointed pre- and post-operation, have been recommended to be canceled in hospitals. The wards of the hospitals’ main building were allocated to patients with COVID-19.
Supporting IBD Patients in COVID-19 Pandemic

Most of the patients with IBD who had admitted to hospitals for non-urgent reasons were recognized and discharged from the hospital, and their care was continued on an outpatient basis. On the other hand, hospitalized patients with IBD were isolated to decrease contact with the virus. Supporting the regular visits of IBD patients were advised to be performed based on the type of needed care. The first step to discover the type of care for IBD patients was the assessment of the basal status of IBD in each patient and stratification based on the risk factors of IBD progression. American Gastroenterology Association risk stratification.13,14 was used for describing the basal status of the patients and the risk of disease progression for all registered patients. After categorizing the patients based on the status of IBD, the risk factors of COVID-19 infection among these patients were assessed.

Telehealth was recommended to be used for visiting the patients with IBD for providing high-quality care without the risk of COVID-19 transmission.15 as much as possible (table 4). However, the following outpatient care has been recommended to be performed by safe outpatient clinics. These clinics have been determined for performing laboratory assessment, imaging, and wound/stoma care.

We advised patients and physicians to cancel elective colonoscopic examinations. Colonoscopic examinations were performed only for new IBD patients with severe active disease who were candidates for biological therapy or patients with a severe flare-up. In other cases, colonoscopic examinations were replaced by fecal calprotectin.16

With this purpose, the British Society of Gastroenterology has grouped the patients based on the presence of COVID-19 symptoms, previous contact with a susceptible case of COVID-19, and history of traveling to high-risk areas to provide the safety of both personnel of clinics and patients during any procedure. Patients with a history of traveling to high-risk areas or previous contact with a susceptible case of COVID-19 was considered as an intermediate-risk group. However, patients who had at least one symptom other than the history of traveling and contact have been considered as high-risk groups.12 Others who had no history of contact and travel without any presentations have been considered as a low-risk group.

The personal protective equipment (PPE) was determined based on this grouping system, shown in Table 5.17

We recommended that all patients were informed through a phone call for referring to clinics and recommended to wear masks and gloves. They got to triage at the entrance based on the clinical presentation (measuring body temperature, asking about the presence of symptoms), and histories of contact and traveling. No relatives were allowed to enter the clinic. The seating arrangement for awaiting patients was conducted by highlighting the chairs, which had a distance of approximately 1.8 meters. It was recommended to use the minimum furniture and equipment. The rooms had negative pressure. The procedural room, including colonoscopy and infusion, was a dedicated room. The minimum number of personnel, including nurses and physicians, were present in clinics. During the procedure, social distancing was

---

Table 3: Risk stratification of the British Society of Gastroenterology (BSG)

<table>
<thead>
<tr>
<th>Risk stratification of the British Society of Gastroenterology (BSG)</th>
<th>Highest risk</th>
<th>Moderate risk</th>
<th>Lowest risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advise SHIELDING (compulsive self-isolation)</td>
<td>Patients with the following medications:</td>
<td>Patients on the following medications:</td>
<td>Patients on the following medications:</td>
</tr>
<tr>
<td>- IBD patients with comorbidities and/or age≥70 years and are on treatment for IBD except for 5ASA, budesonide, beclometasone, or rectal therapies</td>
<td>- Immunosuppressive/biological treatment</td>
<td>- 5ASA</td>
<td>- 5ASA</td>
</tr>
<tr>
<td>- IBD patients, regardless of comorbidity and age, meet at least one of the following criteria:</td>
<td>- Anti-TNF therapy (infliximab, adalimumab, golimumab)</td>
<td>- Orally administered and topical use of steroid (budesonide and beclometasone)</td>
<td>- Orally administered and topical use of steroid (budesonide and beclometasone)</td>
</tr>
<tr>
<td>• Oral or intravenous prednisolone more than 20 mg daily</td>
<td>- Janus kinase inhibitors (tofacitinib)</td>
<td>- Therapies for bile-acid diarrhea (colestyramine, colesvelam, colestipol)</td>
<td>- Therapies for bile-acid diarrhea (colestyramine, colesvelam, colestipol)</td>
</tr>
<tr>
<td>• New induction with combo therapy (starting biologics within previous 6 weeks)</td>
<td>- Thiopurine (azathioprine, mercaptopurine, thioguanine)</td>
<td>- Anti-diarrheal agents such as loperamide</td>
<td>- Anti-diarrheal agents such as loperamide</td>
</tr>
<tr>
<td>• Moderately to severely active disease despite the immunosuppressive/immunomodulator/biologics</td>
<td>- A calcineurin inhibitor (tacrolimus, cyclosporine)</td>
<td>- Antibiotics for bacterial overgrowth or perianal disease</td>
<td>- Antibiotics for bacterial overgrowth or perianal disease</td>
</tr>
</tbody>
</table>

---

Middle East J Dig Dis/ Vol.12/ No.4/ October 2020
considered between the personnel and the patients. The steps of disinfection were performed for scopes of colonoscopy and infusion after doing the procedure. Especially more observation was conducted if the patients were categorized in the high-risk group.

This study was approved by the ethics committee of Tehran University of Medical Sciences. Informed consent was obtained from the study participants.

RESULTS

Based on the recommended protocol of IRCC, patients with IBD made 1920 hotline calls from February until April. Among the patients with suspicious presentations, 14 patients were diagnosed as having COVID-19 based on the findings of CT scans. Additionally, 1782 patients of five provinces with a higher rate of IBD actively phone-called and were evaluated in terms of COVID-19 presentations. By this active follow-up, 37 definite cases were diagnosed. Therefore, 51 patients with underlying IBD were diagnosed as having COVID-19.

DISCUSSION

In this descriptive study, we described the study protocol of the supporting system for patients with IBD in Iran, which aimed to reduce COVID-19 infection among such patients, adjust the routine care of the patients, and detect the IBD patients with COVID-19 infection.

There are several disagreements about whether underlying IBD increases the risk of COVID-19 infection. However, the best opinion for IBD patients is the use of qualified hygiene for washing hands, nose/mouth covering with a tissue, and limiting close contact with upper/lower respiratory tract symptomatic persons. Nevertheless, healthcare systems of various countries are planning for IBD patients to limit their risk of COVID-19 infection.

The general recommendations for the prevention of COVID-19 were announced for IBD patients in Milan and China. Elective surgeries were postponed, and urgent patients were admitted to the hospital and assessed in gastroenterology and surgical units. Multidisciplinary team meetings were held virtually. A checklist was designed to investigate the signs and symptoms of COVID-19, and PPE principles were implemented in outpatient clinics and hospitals. To avoid crowding, the patients’ visits were re-scheduled.

Many patients with IBD have simultaneous other diseases, including systemic lupus erythematosus, celiac, and malignancies. With the expansion of the

<table>
<thead>
<tr>
<th>Table 4: The outline of telehealth visits for patients with IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Table 5: The BSG risk stratification for the usage of Personal Protective Equipment</strong></td>
</tr>
<tr>
<td><strong>Personal Protective Equipment (PPE)</strong></td>
</tr>
<tr>
<td><strong>Low-risk</strong></td>
</tr>
<tr>
<td>Surgical mask</td>
</tr>
<tr>
<td>Hairnet</td>
</tr>
<tr>
<td>Goggles</td>
</tr>
<tr>
<td>Single-use gown</td>
</tr>
<tr>
<td>Gloves</td>
</tr>
</tbody>
</table>
database, and due to the novelty of SARS-CoV-2, it is crucial to observe the effects and outcomes of COVID-19 on patients with IBD or patients with IBD and its concurrence diseases.

Based on the experiences achieved during the COVID-19 pandemic, it is crucial to conduct alternative strategic plans for IBD patients to prevent the optimal care interferences that can occur during a disease epidemic for such patients. Designing strategic plans with simultaneous education of IBD patients and physicians can decrease the severe outcomes and severe complications.

The data is now being completed for Iranian IBD cases through IRCC IBD protocol. The structure of the protocol is dynamic and is based on the ongoing education of both IBD patients and physicians, which is one of the duties of IRCC.

This study will allow analyses of information about Iranian IBD patients with Covid-19 infection. These data will provide: 1) Patients’ demographics and clinical characteristics; 2) Patients’ outcomes; 3) Treatment strategies and their potential efficacy and safety.

ACKNOWLEDGMENT

We thank all collaborators of IRCC who shared their cases with our team. Also, We thank all colleagues in Tehran, Sari, Rasht, Mashhad, Neyshabour, and Ghom research centers that provide logistic support for setting up of this study.

ETHICAL APPROVAL

There is nothing to be declared.

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

REFERENCES


